35.95
price up icon4.04%   1.395
after-market Handel nachbörslich: 36.03 0.075 +0.21%
loading
Schlusskurs vom Vortag:
$34.56
Offen:
$34.87
24-Stunden-Volumen:
2.65M
Relative Volume:
1.58
Marktkapitalisierung:
$4.33B
Einnahmen:
$10.12M
Nettoeinkommen (Verlust:
$-280.49M
KGV:
-12.44
EPS:
-2.89
Netto-Cashflow:
$-188.51M
1W Leistung:
+7.23%
1M Leistung:
+23.85%
6M Leistung:
+12.64%
1J Leistung:
-22.56%
1-Tages-Spanne:
Value
$34.25
$36.03
1-Wochen-Bereich:
Value
$32.72
$37.59
52-Wochen-Spanne:
Value
$21.51
$56.00

Avidity Biosciences Inc Stock (RNA) Company Profile

Name
Firmenname
Avidity Biosciences Inc
Name
Telefon
858-401-7900
Name
Adresse
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Name
Mitarbeiter
391
Name
Twitter
Name
Nächster Verdiensttermin
2024-12-07
Name
Neueste SEC-Einreichungen
Name
RNA's Discussions on Twitter

Vergleichen Sie RNA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
RNA
Avidity Biosciences Inc
35.95 4.37B 10.12M -280.49M -188.51M -2.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
468.41 120.60B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.14 60.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
330.55 42.87B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
598.79 36.23B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
305.74 31.54B 3.81B -644.79M -669.77M -6.24

Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-10 Fortgesetzt Goldman Buy
2025-06-24 Eingeleitet Bernstein Outperform
2025-06-17 Eingeleitet Wolfe Research Outperform
2025-06-11 Eingeleitet Raymond James Strong Buy
2025-03-13 Eingeleitet Citigroup Buy
2025-03-12 Eingeleitet BMO Capital Markets Outperform
2025-03-07 Eingeleitet Scotiabank Sector Outperform
2024-12-20 Eingeleitet H.C. Wainwright Buy
2024-11-26 Eingeleitet RBC Capital Mkts Outperform
2024-09-24 Eingeleitet Goldman Buy
2024-08-28 Eingeleitet Barclays Overweight
2024-05-03 Eingeleitet BofA Securities Buy
2024-03-14 Eingeleitet Cantor Fitzgerald Overweight
2023-05-22 Hochstufung Evercore ISI In-line → Outperform
2023-03-31 Herabstufung Evercore ISI Outperform → In-line
2022-07-20 Eingeleitet Chardan Capital Markets Buy
2022-07-12 Eingeleitet Raymond James Strong Buy
2021-09-07 Eingeleitet Evercore ISI Outperform
2021-06-17 Eingeleitet Needham Buy
2021-04-26 Fortgesetzt Credit Suisse Outperform
2020-07-07 Eingeleitet Cowen Outperform
2020-07-07 Eingeleitet Credit Suisse Outperform
2020-07-07 Eingeleitet SVB Leerink Outperform
2020-07-07 Eingeleitet Wells Fargo Overweight
Alle ansehen

Avidity Biosciences Inc Aktie (RNA) Neueste Nachrichten

pulisher
Jul 28, 2025

Trendline Breach Raises Concern for Avidity Biosciences Inc. InvestorsStable Entry High Return Opportunities in Focus - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

Avidity Biosciences and the Potential for First-in-Class DM1 Therapy - AInvest

Jul 28, 2025
pulisher
Jul 28, 2025

Avidity completes enrollment for phase 3 trial of DM1 treatment By Investing.com - Investing.com South Africa

Jul 28, 2025
pulisher
Jul 28, 2025

Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission - Yahoo Finance

Jul 28, 2025
pulisher
Jul 28, 2025

What is the dividend policy of Avidity Biosciences Inc. stockDiscover stocks with explosive upside potential - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What are the technical indicators suggesting about Avidity Biosciences Inc.Capitalize on fast-growing stocks today - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How volatile is Avidity Biosciences Inc. stock compared to the marketMaximize your returns with portfolio optimization - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Should I hold or sell Avidity Biosciences Inc. stock in 2025Get alerts on the hottest market movers - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How does Avidity Biosciences Inc. generate profit in a changing economyMassive stock growth - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Is it the right time to buy Avidity Biosciences Inc. stockExpert guidance for superior capital growth - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

Why is Avidity Biosciences Inc. stock attracting strong analyst attentionMaximize gains with timely market signals - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What institutional investors are buying Avidity Biosciences Inc. stockHigh-margin investment plays - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What makes Avidity Biosciences Inc. stock price move sharplyUnlock exclusive stock analysis for investors - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What are analysts’ price targets for Avidity Biosciences Inc. in the next 12 monthsDiscover stocks with superior performance - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 26, 2025

Avidity (RNA) Jumps 9.2% on Drug Candidate’s Breakthrough Therapy Designation - Insider Monkey

Jul 26, 2025
pulisher
Jul 25, 2025

Avidity Biosciences shares climb after FDA grants Breakthrough Therapy designation - MSN

Jul 25, 2025
pulisher
Jul 25, 2025

Is Avidity Biosciences Inc. a good long term investmentFree Stock Market Trend Analysis - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Avidity’s Stock Surge: Time to Act? - timothysykes.com

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Avidity Biosciences Inc. stock priceFree Wealth Planning Blueprint - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

How Avidity Biosciences Inc. stock reacts to Fed policy changesFree Smart Trading Workshop - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

Avidity Biosciences shares rise 1.80% premarket after receiving FDA Breakthrough Therapy designation for DMD treatment. - AInvest

Jul 24, 2025
pulisher
Jul 23, 2025

Avidity Biosciences Gains FDA Breakthrough Therapy Designation - TipRanks

Jul 23, 2025
pulisher
Jul 23, 2025

Why Avidity Biosciences Inc. stock attracts strong analyst attentionFree Stock Movement Tracking - beatles.ru

Jul 23, 2025
pulisher
Jul 23, 2025

Avidity gets FDA breakthrough therapy status for DMD treatment - Seeking Alpha

Jul 23, 2025
pulisher
Jul 23, 2025

FDA grants breakthrough therapy status to Avidity’s DMD drug By Investing.com - Investing.com Canada

Jul 23, 2025
pulisher
Jul 23, 2025

Avidity Biosciences stock rises after FDA grants Breakthrough Therapy status - Investing.com Australia

Jul 23, 2025
pulisher
Jul 23, 2025

Avidity Biosciences stock rises after FDA grants Breakthrough Therapy status By Investing.com - Investing.com India

Jul 23, 2025
pulisher
Jul 23, 2025

Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping - PR Newswire

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Avidity Biosciences Inc. stockOutstanding capital appreciation - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Avidity Biosciences Inc. Stock Analysis and ForecastExtraordinary market timing - jammulinksnews.com

Jul 22, 2025

Finanzdaten der Avidity Biosciences Inc-Aktie (RNA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$77.38
price up icon 10.28%
$37.27
price up icon 0.57%
$105.00
price up icon 3.19%
$26.74
price down icon 2.59%
$111.48
price down icon 1.16%
biotechnology ONC
$305.74
price up icon 3.81%
Kapitalisierung:     |  Volumen (24h):